{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:51:21Z","timestamp":1793332281643,"version":"4.5.0"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004595","name":"Science University of Malaysia","doi-asserted-by":"publisher","award":["2025\/622\/TE113"],"award-info":[{"award-number":["2025\/622\/TE113"]}],"id":[{"id":"10.13039\/501100004595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics: X"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijpx.2026.100521","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:10:56Z","timestamp":1773969056000},"page":"100521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Intranasal drug delivery: Unlocking the nose-to-brain route for central nervous system therapies"],"prefix":"10.1016","volume":"11","author":[{"given":"Ban","family":"Alwali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaigarajan","family":"Parumasivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moawia M.","family":"Al-Tabakha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpx.2026.100521_bb0005","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2022.2163321","article-title":"Formulation and characterization of lamotrigine nasal insert targeted brain for enhanced epilepsy treatment","volume":"30","author":"Abdelmonem","year":"2023","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijpx.2026.100521_bb0010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.5530\/ijper.58.2.64","article-title":"Formulation and optimization of aripiprazole-loaded nanostructured lipid carriers for nose-to-brain delivery","volume":"58","author":"Albaqshi","year":"2024","journal-title":"Indian J. Pharm. Educ. Res."},{"key":"10.1016\/j.ijpx.2026.100521_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119166","article-title":"Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation","volume":"579","author":"Alshweiat","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100521_bb0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5415\/apallergy.0000000000000173","article-title":"A systematic review for improper application of nasal spray in allergic rhinitis: a proposed role of community pharmacist for patient education and counseling in practical setting","volume":"15","author":"Al-Taie","year":"2025","journal-title":"Asia Pac. Allergy"},{"key":"10.1016\/j.ijpx.2026.100521_bb0025","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1208\/s12249-017-0747-8","article-title":"Formulation and evaluation of thermoreversible in situ nasal gels containing mometasone furoate for allergic rhinitis","volume":"18","author":"Altunta\u015f","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpx.2026.100521_bb0030","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1359-6446(02)02452-2","article-title":"Permeability issues in nasal drug delivery","volume":"7","author":"Arora","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijpx.2026.100521_bb0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1208\/s12249-022-02259-z","article-title":"Characterizing the effects of nasal prong interfaces on aerosol deposition in a preterm infant nasal model","volume":"23","author":"Bass","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpx.2026.100521_bb0040","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1111\/all.16116","article-title":"AM-301, a barrier-forming nasal spray, versus saline spray in seasonal allergic rhinitis: a randomized clinical trial","volume":"79","author":"Becker","year":"2024","journal-title":"Allergy"},{"issue":"1\u20132","key":"10.1016\/j.ijpx.2026.100521_bb0045","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0169-409X(97)00063-X","article-title":"Effects of physicochemical properties and other factors on systemic nasal drug delivery","volume":"29","author":"Behl","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2026.100521_bb0050","article-title":"Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses","volume":"9","author":"Beule","year":"2010","journal-title":"GMS Curr. Top. Otorhinolaryngol. Head Neck Surg."},{"key":"10.1016\/j.ijpx.2026.100521_bb0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000321044","article-title":"Nasal drug delivery in humans","volume":"40","author":"Bitter","year":"2011","journal-title":"Curr. Probl. Dermatol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0060","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1164\/rccm.201011-1783OC","article-title":"Potential of nasopharynx-associated lymphoid tissue for vaccine responses in the airways","volume":"183","author":"Brandtzaeg","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijpx.2026.100521_bb0065","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/head.12472","article-title":"A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (the TARGET study)","volume":"55","author":"Cady","year":"2015","journal-title":"Headache"},{"key":"10.1016\/j.ijpx.2026.100521_bb0070","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1208\/s12249-011-9678-y","article-title":"Formulation and evaluation of in situ gelling systems for intranasal administration of gastrodin","volume":"12","author":"Cai","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpx.2026.100521_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221330","article-title":"Nasal sprayed particle deposition in a human nasal cavity under different inhalation conditions","volume":"14","author":"Calmet","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.ijpx.2026.100521_bb0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijpharm.2008.08.042","article-title":"In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate","volume":"365","author":"Cao","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100521_bb0085","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jconrel.2014.05.003","article-title":"Chitosan in nasal delivery systems for therapeutic drugs","volume":"190","author":"Casettari","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2026.100521_bb0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/2231-4040.90876","article-title":"A review on mucoadhesive polymer used in nasal drug delivery system","volume":"2","author":"Chaturvedi","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"10.1016\/j.ijpx.2026.100521_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115196","article-title":"Intranasal drug delivery: the interaction between nanoparticles and the nose-to-brain pathway","volume":"207","author":"Chen","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2026.100521_bb0100","article-title":"The nose has it: opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters","volume":"21","author":"Chung","year":"2023","journal-title":"Epilepsy Behav. Rep."},{"key":"10.1016\/j.ijpx.2026.100521_bb0105","series-title":"SA55 Novel Coronavirus Broad-Spectrum Neutralizing Antibody Nasal Spray in Health People (NCT06048393)","author":"ClinicalTrials.gov","year":"2023"},{"key":"10.1016\/j.ijpx.2026.100521_bb0110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1089\/jamp.2022.0005","article-title":"Delivery of dihydroergotamine mesylate to the upper nasal space for the acute treatment of migraine: technology in action","volume":"35","author":"Cooper","year":"2022","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpx.2026.100521_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030524","article-title":"Human Lactobacillus biosurfactants as natural excipients for nasal drug delivery of hydrocortisone","volume":"14","author":"Corazza","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1\u20132","key":"10.1016\/j.ijpx.2026.100521_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","article-title":"Intranasal delivery: Physicochemical and therapeutic aspects","volume":"337","author":"Costantino","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100521_bb0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.ijpx.2026.100521_bb0130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ca.22255","article-title":"Anatomic description of the middle meatus and classification of the hiatus semilunaris into five types based upon morphological characteristics","volume":"27","author":"Dahlstrom","year":"2014","journal-title":"Clin. Anat."},{"issue":"1","key":"10.1016\/j.ijpx.2026.100521_bb0135","article-title":"Formulation, design and strategies for efficient nanotechnology-based nasal delivery systems","volume":"1","author":"De Barros","year":"2022","journal-title":"RPS Pharma Pharmacol. Rep."},{"key":"10.1016\/j.ijpx.2026.100521_bb0140","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100521_bb0145","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","article-title":"Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review","volume":"3","author":"Djupesland","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ijpx.2026.100521_bb0150","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.MLG.0000199741.08517.99","article-title":"Breath actuated device improves delivery to target sites beyond the nasal valve","volume":"116","author":"Djupesland","year":"2006","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ijpx.2026.100521_bb0155","first-page":"175","article-title":"Deposition of drugs in the nose and sinuses with an exhalation delivery system vs conventional nasal spray or high-volume irrigation in draf II\/III post-surgical anatomy","volume":"58","author":"Djupesland","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.ijpx.2026.100521_bb0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40035-025-00481-w","article-title":"Nose-to-brain drug delivery: from bench to bedside","volume":"14","author":"Drath","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.ijpx.2026.100521_bb0165","series-title":"Sterile Product Development: Formulation, Process, Quality and Regulatory Considerations","first-page":"99","article-title":"Considerations for the development of nasal dosage forms","author":"Ehrick","year":"2013"},{"key":"10.1016\/j.ijpx.2026.100521_bb0170","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Erd\u0151","year":"2018","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ijpx.2026.100521_bb0175","doi-asserted-by":"crossref","DOI":"10.1063\/5.0024264","article-title":"Large eddy simulations of airflow and particle deposition in pulsating bi-directional nasal drug delivery","volume":"32","author":"Farnoud","year":"2020","journal-title":"Phys. Fluids"},{"key":"10.1016\/j.ijpx.2026.100521_bb0180","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/pharmaceutics11050239","article-title":"Vibrating mesh nebulisation of pro-antimicrobial peptides for use in cystic fibrosis","volume":"11","author":"Forde","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100521_bb0185","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ijbiomac.2020.11.047","article-title":"Nose-to-brain delivery of teriflunomide-loaded lipid-based carbopol-gellan gum nanogel for glioma: Pharmacological and in vitro cytotoxicity studies","volume":"167","author":"Gadhave","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0190","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pharma.2022.08.010","article-title":"Nose-to-brain delivery of paliperidone palmitate poloxamer-guar gum nanogel: Formulation, optimization and pharmacological studies in rats","volume":"81","author":"Gadhave","year":"2023","journal-title":"Ann. Pharm. Fr."},{"issue":"3","key":"10.1016\/j.ijpx.2026.100521_bb0195","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/pharmaceutics10030116","article-title":"Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa","volume":"10","author":"G\u00e4nger","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100521_bb0200","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40005-020-00482-z","article-title":"Factors influencing drug deposition in the nasal cavity upon delivery via nasal sprays","volume":"50","author":"Gao","year":"2020","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.ijpx.2026.100521_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11030113","article-title":"Strategies to enhance drug absorption via nasal and pulmonary routes","volume":"11","author":"Ghadiri","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100521_bb0210","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/17425247.2019.1597051","article-title":"Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders","volume":"16","author":"Gholizadeh","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ijpx.2026.100521_bb0215","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11095-020-02913-w","article-title":"Nasal powder formulation of tranexamic acid and hyaluronic acid for the treatment of epistaxis","volume":"37","author":"Gomes dos Reis","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2026.100521_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123809","article-title":"Rivastigmine nasal spray for the treatment of Alzheimer\u2019s disease: olfactory deposition and brain delivery","volume":"652","author":"Guo","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100521_bb0225","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/08982104.2023.2214619","article-title":"Nose to brain delivery of naringin loaded transniosomes for epilepsy: formulation, characterisation, blood-brain distribution and in vivo pharmacodynamic evaluation","volume":"34","author":"Gupta","year":"2024","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ijpx.2026.100521_bb0230","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/1061186X.2024.2433557","article-title":"Development of in vitro and in vivo evaluation of mucoadhesive in-situ gel for intranasal delivery of vinpocetine","volume":"33","author":"Hard","year":"2025","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.ijpx.2026.100521_bb0235","first-page":"249","article-title":"An overview on nasal drug delivery system","volume":"12","author":"Hemalatha","year":"2022","journal-title":"Asian J. Pharm. Res."},{"key":"10.1016\/j.ijpx.2026.100521_bb0240","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1023\/A:1015872617511","article-title":"Effects of absorption enhancers on human nasal tissue ciliary movement in vitro","volume":"7","author":"Hermens","year":"1990","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2026.100521_bb0245","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.addr.2020.07.006","article-title":"Emerging trends in inhaled drug delivery","volume":"157","author":"Hickey","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2026.100521_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125598","article-title":"Advances in cell-penetrating peptide-based nose-to-brain drug delivery systems","volume":"678","author":"Hong","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100521_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21050658","article-title":"Cytotoxicity of different excipients on RPMI 2650 human nasal epithelial cells","volume":"21","author":"Horv\u00e1th","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ijpx.2026.100521_bb0260","doi-asserted-by":"crossref","unstructured":"Hu C, Zhou Y, Meng X, Li J, Chen J, Ying Z, et al. Safety and intranasal retention of a broad-spectrum Anti-SARS-CoV-2 monoclonal antibody SA55 nasal spray in healthy volunteers: a phase I clinical trial. Pharmaceutics 2024;17:43. Doi: https:\/\/doi.org\/10.3390\/pharmaceutics17010043.","DOI":"10.3390\/pharmaceutics17010043"},{"key":"10.1016\/j.ijpx.2026.100521_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1341295","article-title":"Research progress in brain-targeted nasal drug delivery","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ijpx.2026.100521_bb0270","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/cercor\/bhac085","article-title":"The human vestibular cortex: functional anatomy of OP2, its connectivity and the effect of vestibular disease","volume":"33","author":"Ibitoye","year":"2023","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.ijpx.2026.100521_bb0275","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1007\/s13346-024-01528-7","article-title":"Nose to brain delivery of mirtazapine via lipid nanocapsules: Preparation, statistical optimization, radiolabeling, in vivo biodistribution and pharmacokinetic study","volume":"14","author":"Ibrahim","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ijpx.2026.100521_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100521_bb0285","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery\u2014possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2026.100521_bb0290","series-title":"World Health Organization. International Chemical Safety Card (ICSC) 1584: Benzalkonium Chloride","author":"International Labour Organization","year":"2021"},{"key":"10.1016\/j.ijpx.2026.100521_bb0295","article-title":"Delivering therapy to the olfactory cleft: a comparison of the various methods of administering topical nasal medications","volume":"16","author":"Jacobson","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ijpx.2026.100521_bb0300","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40005-022-00589-5","article-title":"Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors","volume":"53","author":"Jeong","year":"2023","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.ijpx.2026.100521_bb0305","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4168\/aair.2019.11.3.306","article-title":"Influence of intranasal drugs on human nasal mucociliary clearance and ciliary beat frequency","volume":"11","author":"Jiao","year":"2019","journal-title":"Allergy Asthma Immunol. Res."},{"key":"10.1016\/j.ijpx.2026.100521_bb0310","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/mp100029t","article-title":"Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures","volume":"7","author":"Johnson","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2026.100521_bb0315","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/10837450.2018.1514523","article-title":"Montelukast nasal spray: formulation development and in vitro evaluation","volume":"24","author":"Jullaphant","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020419","article-title":"Development and comparative in vitro and in vivo study of BNN27 mucoadhesive liposomes and nanoemulsions for nose-to-brain delivery","volume":"15","author":"Kannavou","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.ijpx.2026.100521_bb0325","first-page":"49","article-title":"Formulation and evaluation nasal in situ gel of rizatriptan","volume":"9","author":"Kantrodiya","year":"2019","journal-title":"Int. J. Pharm. Res. Technol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0330","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","article-title":"Intranasal drug delivery: opportunities and toxicologic challenges during drug development","volume":"12","author":"Keller","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ijpx.2026.100521_bb0335","article-title":"Intranasal transfersomal based in situ gel for augmenting methylphenidate bioavailability and brain delivery: in vitro and in vivo evaluation","volume":"101","author":"Khalil","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0340","doi-asserted-by":"crossref","DOI":"10.5812\/jjnpp-127106","article-title":"Development of a natural preservative system in fluticasone propionate nasal spray formulation using eucalyptus globulus essential oil","volume":"17","author":"Kheirkhah Rahimabadi","year":"2022","journal-title":"Jundishapur J. Nat. Pharm. Prod."},{"key":"10.1016\/j.ijpx.2026.100521_bb0345","series-title":"Direct Nose-to-Brain Drug Delivery","first-page":"3","article-title":"An overview of anatomical and physiological aspects of the nose and the brain","author":"Khunt","year":"2021"},{"key":"10.1016\/j.ijpx.2026.100521_bb0350","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nri1439","article-title":"NALT- versus Peyer\u2019s-patch-mediated mucosal immunity","volume":"4","author":"Kiyono","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0355","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.3390\/pharmaceutics15102439","article-title":"The path from nasal tissue to nasal mucosa on chip: part 2\u2014advanced microfluidic nasal in vitro model for drug absorption testing","volume":"15","author":"Koch","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100521_bb0360","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2147\/IJN.S439181","article-title":"Recent advances in intranasal administration for brain-targeting delivery: a comprehensive review of lipid-based nanoparticles and stimuli-responsive gel formulations","volume":"19","author":"Koo","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijpx.2026.100521_bb0365","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s11095-011-0417-6","article-title":"Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast","volume":"28","author":"Kundoor","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2026.100521_bb0370","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijpharm.2017.09.018","article-title":"Physicochemical properties of mucus and their impact on transmucosal drug delivery","volume":"532","author":"Leal","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100521_bb0375","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaci.2018.06.010","article-title":"NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis","volume":"143","author":"Leopold","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0380","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.bja.2017.11.100","article-title":"Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine","volume":"120","author":"Li","year":"2018","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ijpx.2026.100521_bb0385","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/head.13165","volume":"57","author":"Lipton","year":"2017","journal-title":"Headache"},{"key":"10.1016\/j.ijpx.2026.100521_bb0390","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/jamp.2018.1508","article-title":"Devices for improved delivery of nebulized pharmaceutical aerosols to the lungs","volume":"32","author":"Longest","year":"2019","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpx.2026.100521_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106630","article-title":"A comprehensive review of advanced nasal delivery: specially insulin and calcitonin","volume":"192","author":"Luo","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100521_bb0400","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13071079","article-title":"In vitro evaluation of nasal aerosol depositions: an insight for direct nose to brain drug delivery","volume":"13","author":"Maaz","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100521_bb0405","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.3390\/pharmaceutics15082119","article-title":"Optimizing absorption for intranasal delivery of drugs targeting the central nervous system using alkylsaccharide permeation enhancers","volume":"15","author":"Madden","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100521_bb0410","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/pharmaceutics11070339","article-title":"Transmucosal absorption enhancers in the drug delivery field","volume":"11","author":"Maher","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100521_bb0415","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/jamp.2007.0659","article-title":"Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models","volume":"21","author":"Mall","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpx.2026.100521_bb0420","first-page":"4942","article-title":"Design and characterization of phase transition system of zolmitriptan hydrochloride for nasal drug delivery dystem","volume":"13","author":"Malviya","year":"2020","journal-title":"Int. J. Pharm. Sci. Nanotechnol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0425","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/alr.20057","article-title":"Prospective evaluation of aerosol delivery by a powered nasal nebulizer in the cadaver model","volume":"1","author":"Manes","year":"2011","journal-title":"Int. Forum. Allergy Rhinol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0430","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.3390\/jcm10112468","article-title":"Nasal delivery of acute medications for migraine: the upper versus lower nasal space","volume":"10","author":"Martin","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijpx.2026.100521_bb0435","first-page":"1247","article-title":"Microbial integrity test for preservative-free multidose eyedroppers or nasal spray pumps","volume":"81","author":"Marx","year":"2019","journal-title":"Pharm. Ind."},{"key":"10.1016\/j.ijpx.2026.100521_bb0440","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/adt.2022.088","article-title":"Preparation and optimization of liposome containing thermosensitive in Situ nasal hydrogel system for brain delivery of sumatriptan succinate","volume":"21","author":"Mathure","year":"2023","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0445","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s43556-020-00014-z","article-title":"Developing inhaled protein therapeutics for lung diseases","volume":"1","author":"Matthews","year":"2020","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.ijpx.2026.100521_bb0450","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/jfb13040229","article-title":"Developing of SiO2 nanoshells loaded with fluticasone propionate for potential nasal drug delivery: Determination of pro-inflammatory cytokines through mRNA expression","volume":"13","author":"Mehmood","year":"2022","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.ijpx.2026.100521_bb0455","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jconrel.2023.01.070","article-title":"Nasal administration of a temozolomide-loaded thermoresponsive nanoemulsion reduces tumor growth in a preclinical glioblastoma model","volume":"355","author":"Michels","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2026.100521_bb0460","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/coa.13690","article-title":"A comparison between mygind and kaiteki positions in administration of drops to the olfactory cleft","volume":"46","author":"Milk","year":"2021","journal-title":"Clin. Otolaryngol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0465","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/713714452","article-title":"Drug transport into the mammalian brain: the nasal pathway and its specific metabolic barrier","volume":"10","author":"Minn","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijpx.2026.100521_bb0470","article-title":"Effect of mucociliary clearance on the particulate airflow inside the nasal sinus and its role in increasing the residence time and absorption of drugs inside the upper respiratory pathway","volume":"89","author":"Modaresi","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0475","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4602651","article-title":"Nasal delivery devices: a comparative study on cadaver model","volume":"2019","author":"Moffa","year":"2019","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.ijpx.2026.100521_bb0480","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.3390\/jcm12103492","article-title":"Comparison of intranasal steroid application using nasal spray and Spray-Sol to treat allergic rhinitis: a preliminary investigation","volume":"12","author":"Moffa","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijpx.2026.100521_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111236","article-title":"Intranasal lipid nanocapsules for systemic delivery of nimodipine into the brain: in vitro optimization and in vivo pharmacokinetic study","volume":"116","author":"Mohsen","year":"2020","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ijpx.2026.100521_bb0490","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3390\/pharmaceutics13101640","article-title":"Nose to brain delivery of phenytoin sodium loaded nano lipid carriers: formulation, drug release, permeation and in vivo pharmacokinetic studies","volume":"13","author":"Nair","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100521_bb0495","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000526423","article-title":"Efficacy and safety of a drug-free, barrier-forming nasal spray for allergic rhinitis: Randomized, open-label, crossover noninferiority trial","volume":"184","author":"Nehrig","year":"2023","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0500","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nri1777","article-title":"Mucosal vaccines: the promise and the challenge","volume":"6","author":"Neutra","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13060795","article-title":"A dry powder platform for nose-to-brain delivery of dexamethasone: formulation development and nasal deposition studies","volume":"13","author":"Ni\u017ei\u0107 Nodilo","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100521_bb0510","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/alr.23043","article-title":"Efficacy of the exhalation delivery system with fluticasone in patients with chronic rhinosinusitis with nasal polyps whose symptoms recur after sinus surgery","volume":"13","author":"Ow","year":"2023","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0515","series-title":"Spray Drying Pharmaceutical Products for Nasal Delivery: The Effects of Feed Solution Properties and Operating Conditions on Particle Size and Density","first-page":"427","author":"Ozmen","year":"2023"},{"key":"10.1016\/j.ijpx.2026.100521_bb0520","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.3390\/molecules14093754","article-title":"Nasal delivery of high molecular weight drugs","volume":"14","author":"Ozsoy","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.ijpx.2026.100521_bb0525","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/alr.22141","article-title":"EXHANCE-12: 1-year study of the exhalation delivery system with fluticasone (EDS-FLU) in chronic rhinosinusitis","volume":"8","author":"Palmer","year":"2018","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0530","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425247.2013.790887","article-title":"Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood\u2013brain barrier: an excellent platform for brain targeting","volume":"10","author":"Pardeshi","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ijpx.2026.100521_bb0535","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21053\/ceo.2021.00654","article-title":"Clinical practice guideline: nasal irrigation for chronic rhinosinusitis in adults","volume":"15","author":"Park","year":"2022","journal-title":"Clin. Exp. Otorhinolaryngol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0540","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11060265","article-title":"Nasal administration and plasma pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the treatment of Osteoporosis","volume":"11","author":"Pearson","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100521_bb0545","first-page":"220","article-title":"Research and development of drug delivery systems based on drug transporter and nano-formulation","volume":"15","author":"Peng","year":"2020","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.ijpx.2026.100521_bb0550","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100521_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120040","article-title":"Intranasal fosphenytoin: the promise of phosphate esters in nose-to-brain delivery of poorly soluble drugs","volume":"592","author":"Pires","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2026.100521_bb0560","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.colsurfb.2018.11.025","article-title":"Lamotrigine encapsulated intra-nasal nanoliposome formulation for epilepsy treatment: Formulation design, characterization and nasal toxicity study","volume":"174","author":"Praveen","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ijpx.2026.100521_bb0565","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1080\/02786826.2014.931566","article-title":"A Comparison of the deposition patterns of different nasal spray formulations using a nasal cast","volume":"48","author":"Pu","year":"2014","journal-title":"Aerosol Sci. Tech."},{"issue":"6","key":"10.1016\/j.ijpx.2026.100521_bb0570","doi-asserted-by":"crossref","DOI":"10.1002\/mame.202400356","article-title":"In situ gels for nasal delivery: Formulation, characterization and applications","volume":"310","author":"Qian","year":"2025","journal-title":"Macromol. Mater. Eng."},{"issue":"10","key":"10.1016\/j.ijpx.2026.100521_bb0575","doi-asserted-by":"crossref","DOI":"10.1063\/5.0296863","article-title":"Progress in nasal drug delivery research based on biomaterials","volume":"13","author":"Qiu","year":"2025","journal-title":"APL Mater."},{"key":"10.1016\/j.ijpx.2026.100521_bb0580","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jddst.2019.01.040","article-title":"Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: Formulation, optimization and in vivo characterization","volume":"51","author":"Rajput","year":"2019","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0585","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/pharmaceutics10040206","article-title":"The Role of combined penetration enhancers in nasal microspheres on in vivo drug bioavailability","volume":"10","author":"Rassu","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100521_bb0590","series-title":"Novel Platforms for Drug Delivery Applications","first-page":"569","article-title":"Nasal and pulmonary routes of drug delivery","author":"Saalbach","year":"2023"},{"key":"10.1016\/j.ijpx.2026.100521_bb0595","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/ph17091180","article-title":"Review of intranasal active pharmaceutical ingredient delivery systems","volume":"17","author":"Safarov","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijpx.2026.100521_bb0600","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/03639045.2023.2183724","article-title":"Nasal residence time and rheological properties of a new bentonite-based thixotropic gel emulsion nasal spray \u2013 AM-301","volume":"49","author":"Sailer","year":"2023","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpx.2026.100521_bb0605","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s43556-020-00019-8","article-title":"Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS","volume":"1","author":"Sarma","year":"2020","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.ijpx.2026.100521_bb0610","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4155\/tde-2019-0086","article-title":"Nasal formulations for drug administration and characterization of nasal preparations in drug delivery","volume":"11","author":"Scherlie\u00df","year":"2020","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ijpx.2026.100521_bb0615","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s43094-020-00156-5","article-title":"Comparative evaluation of intranasally delivered quetiapine loaded mucoadhesive microemulsion and polymeric nanoparticles for brain targeting: pharmacokinetic and gamma scintigraphy studies","volume":"7","author":"Shah","year":"2021","journal-title":"Fut. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100521_bb0620","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1081\/DDC-120025457","article-title":"Comparison of the flow properties of aqueous suspension corticosteroid nasal sprays under differing sampling conditions","volume":"29","author":"Sharpe","year":"2003","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpx.2026.100521_bb0625","first-page":"25","article-title":"EXHANCE-3: a cohort study of the exhalation delivery system with fluticasone for chronic sinusitis with or without nasal polyps","volume":"58","author":"Sher","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.ijpx.2026.100521_bb0630","first-page":"466","article-title":"Development and evaluation of in situ nasal gel formulations of loratadine","volume":"10","author":"Sherafudeen","year":"2015","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100521_bb0635","doi-asserted-by":"crossref","DOI":"10.3390\/polym12112589","article-title":"Tailoring midazolam-loaded chitosan nanoparticulate formulation for enhanced brain delivery via intranasal route","volume":"12","author":"Shrestha","year":"2020","journal-title":"Polymers (Basel)"},{"issue":"3","key":"10.1016\/j.ijpx.2026.100521_bb0640","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/head.13476","article-title":"STOP 101: a phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by an I-123 precision olfactory delivery (POD\u00ae) device, in healthy adult subjects","volume":"59","author":"Shrewsbury","year":"2019","journal-title":"Headache"},{"issue":"9","key":"10.1016\/j.ijpx.2026.100521_bb0645","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v10i9.2971","article-title":"The pharmacokinetics of drug delivery to the upper nasal space: a review of INP105 development","volume":"10","author":"Shrewsbury","year":"2022","journal-title":"Med. Res. Arch."},{"issue":"6","key":"10.1016\/j.ijpx.2026.100521_bb0650","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3390\/pharmaceutics15061720","article-title":"The upper nasal space: option for systemic drug delivery, mucosal vaccines and \u201cnose-to-brain\u201d","volume":"15","author":"Shrewsbury","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100521_bb0655","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1945892418810281","article-title":"NAVIGATE I: Randomized, placebo-controlled, double-blind trial of the exhalation delivery system with fluticasone for chronic rhinosinusitis with nasal polyps","volume":"33","author":"Sindwani","year":"2019","journal-title":"Am. J. Rhinol. Allergy"},{"issue":"6","key":"10.1016\/j.ijpx.2026.100521_bb0660","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3390\/ph18060871","article-title":"Thermosensitive mucoadhesive intranasal in situ gel of risperidone for nose-to-brain targeting: physiochemical and pharmacokinetics study","volume":"18","author":"Singh","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.ijpx.2026.100521_bb0665","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/phar.2669","article-title":"A dose-escalation clinical trial of intranasal ketamine for uncontrolled cancer-related pain","volume":"42","author":"Singh","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijpx.2026.100521_bb0670","article-title":"Niosomes for nose-to-brain delivery of bromocriptine: Formulation development, efficacy evaluation and toxicity profiling","volume":"58","author":"Sita","year":"2020","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0675","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/head.14184","article-title":"STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, precision olfactory delivery (POD) of dihydroergotamine mesylate, over 24\/52 weeks in acute treatment of migraine attacks in adult patients","volume":"61","author":"Smith","year":"2021","journal-title":"Headache"},{"key":"10.1016\/j.ijpx.2026.100521_bb0680","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2217\/pmt-2022-0063","article-title":"INP104: a drug evaluation of a nonoral product for the acute treatment of migraine","volume":"13","author":"Starling","year":"2023","journal-title":"Pain Manag."},{"key":"10.1016\/j.ijpx.2026.100521_bb0685","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000506129","article-title":"The effect of a thixotropic nasal gel on nasal symptoms and inflammatory biomarkers in seasonal allergic rhinitis","volume":"181","author":"Stru\u00df","year":"2020","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2023.101010","article-title":"Development of mucoadhesive in-situ nasal gel formulation for enhanced bioavailability and efficacy of rizatriptan in migraine treatment","volume":"6","author":"Suhagiya","year":"2023","journal-title":"Results Chem."},{"issue":"2","key":"10.1016\/j.ijpx.2026.100521_bb0695","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/pharmaceutics13020246","article-title":"Current perspective on nasal delivery systems for chronic rhinosinusitis","volume":"13","author":"Tai","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2026.100521_bb0700","series-title":"Challenges in delivery of therapeutic genomics and proteomics","first-page":"429","article-title":"Protein and peptide delivery through respiratory pathway","author":"Tandel","year":"2011"},{"key":"10.1016\/j.ijpx.2026.100521_bb0705","first-page":"147","article-title":"Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine","volume":"11","author":"Tepper","year":"2018","journal-title":"Med. Devices (Auckl)"},{"key":"10.1016\/j.ijpx.2026.100521_bb0710","article-title":"Brain targeted intranasal in-situ gelling spray of paroxetine: Formulation, characterization and in vivo evaluation","volume":"62","author":"Thakkar","year":"2021","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0715","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejps.2017.09.027","article-title":"Opportunity and challenges of nasal powders: drug formulation and delivery","volume":"113","author":"Tiozzo Fasiolo","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100521_bb0720","series-title":"Normal Saline","author":"Tonog","year":"2025"},{"key":"10.1016\/j.ijpx.2026.100521_bb0725","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.anl.2020.05.026","article-title":"Challenges in topical therapy of chronic rhinosinusitis: the case of nasal drops application \u2013 a systematic review","volume":"47","author":"Trabut","year":"2020","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.ijpx.2026.100521_bb0730","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/pharmaceutics13030385","article-title":"Nasal powder formulations: In-vitro characterisation of the impact of powders on nasal residence time and sensory effects","volume":"13","author":"Trenkel","year":"2021","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.ijpx.2026.100521_bb0735","first-page":"439","article-title":"Non-invasive strategies for nose-to-brain drug delivery","volume":"10","author":"Trevino","year":"2020","journal-title":"J. Clin. Trials"},{"key":"10.1016\/j.ijpx.2026.100521_bb0740","series-title":"Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products-Chemistry, Manufacturing, and Controls Documentation [Internet]","author":"U.S. Food and Drug Administration (FDA)","year":"2002"},{"key":"10.1016\/j.ijpx.2026.100521_bb0745","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","article-title":"Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives","volume":"57","author":"Ugwoke","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2 Suppl","key":"10.1016\/j.ijpx.2026.100521_bb0750","first-page":"72","article-title":"Mechanisms and solutions for nasal drug delivery \u2013a narrative review","volume":"26","author":"Ulusoy","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.ijpx.2026.100521_bb0755","article-title":"Choosing nasal devices: a dilemma in clinical practice","volume":"94","author":"Varricchio","year":"2023","journal-title":"Acta Biomed"},{"key":"10.1016\/j.ijpx.2026.100521_bb0760","first-page":"1","article-title":"Imaging of intranasal drug delivery to the brain","volume":"10","author":"Veronesi","year":"2020","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ijpx.2026.100521_bb0765","doi-asserted-by":"crossref","first-page":"23684","DOI":"10.1021\/acsnano.4c08279","article-title":"Tailored borneol-modified lipid nanoparticles nasal spray for enhanced nose-to-brain delivery to central nervous system diseases","volume":"18","author":"Wang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.ijpx.2026.100521_bb0770","article-title":"Enhanced delivery of neuroactive drugs via nasal delivery with a self-healing supramolecular gel","volume":"8","author":"Wang","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ijpx.2026.100521_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106623","article-title":"The prescription design and key properties of nasal gel for CNS drug delivery: a review","volume":"192","author":"Wang","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2026.100521_bb0780","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013007362","article-title":"In situ gel-forming system: an attractive alternative for nasal drug delivery","volume":"30","author":"Wang","year":"2013","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ijpx.2026.100521_bb0785","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1021\/acs.molpharmaceut.7b00702","article-title":"Personalized medicine in nasal delivery: the use of patient-specific administration parameters to improve nasal drug targeting using 3D-printed nasal replica casts","volume":"15","author":"Warnken","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2026.100521_bb0790","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1089\/jamp.2019.1549","article-title":"Olfactory targeting of microparticles through Inhalation and bi-directional airflow: effect of particle size and nasal anatomy","volume":"33","author":"Yarragudi","year":"2020","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpx.2026.100521_bb0795","article-title":"Buspirone loaded solid lipid nanoparticles for amplification of nose to brain efficacy: formulation development, optimization by Box-Behnken design, in vitro characterization and in vivo biological evaluation","volume":"61","author":"Yasir","year":"2021","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0800","article-title":"Nose to brain delivery of donepezil through surface modified NLCS: formulation development, optimization, and brain targeting study","volume":"75","author":"Yasir","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ijpx.2026.100521_bb0805","article-title":"Recent advances in 3D printing hydrogel for topical drug delivery","volume":"1","author":"Zhang","year":"2022","journal-title":"MedComm Biomater. Appl."},{"issue":"9","key":"10.1016\/j.ijpx.2026.100521_bb0810","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3390\/pharmaceutics14091974","article-title":"A review of non-invasive drug delivery through respiratory routes","volume":"14","author":"Zhang","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["International Journal of Pharmaceutics: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726000411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726000411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:50:40Z","timestamp":1785210640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590156726000411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":162,"alternative-id":["S2590156726000411"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100521","relation":{},"ISSN":["2590-1567"],"issn-type":[{"value":"2590-1567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal drug delivery: Unlocking the nose-to-brain route for central nervous system therapies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100521"}}